These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31675465)

  • 1. Unique surface-exposed hydrophobic residues in the C1 domain of factor VIII contribute to cofactor function and von Willebrand factor binding.
    Przeradzka MA; Freato N; Boon-Spijker M; van Galen J; van der Zwaan C; Mertens K; van den Biggelaar M; Meijer AB
    J Thromb Haemost; 2020 Feb; 18(2):364-372. PubMed ID: 31675465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
    Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB
    J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphosphate Activates von Willebrand Factor Interaction with Glycoprotein Ib in the Absence of Factor VIII In Vitro.
    Montilla M; Atienza-Navarro I; García-Cozar FJ; Castro C; Rodríguez-Martorell FJ; Ruiz FA
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.
    Castro-Núñez L; Bloem E; Boon-Spijker MG; van der Zwaan C; van den Biggelaar M; Mertens K; Meijer AB
    J Biol Chem; 2013 Jan; 288(1):393-400. PubMed ID: 23168412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII.
    Bovenschen N; Boertjes RC; van Stempvoort G; Voorberg J; Lenting PJ; Meijer AB; Mertens K
    J Biol Chem; 2003 Mar; 278(11):9370-7. PubMed ID: 12522143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
    Wakabayashi H; Fay PJ
    J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
    Kroner PA; Foster PA; Fahs SA; Montgomery RR
    Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
    Przeradzka MA; Meems H; van der Zwaan C; Ebberink EHTM; van den Biggelaar M; Mertens K; Meijer AB
    Biochem J; 2018 Sep; 475(17):2819-2830. PubMed ID: 30111575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
    Saenko E; Sarafanov A; Greco N; Shima M; Loster K; Schwinn H; Josic D
    J Chromatogr A; 1999 Aug; 852(1):59-71. PubMed ID: 10480230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII A3 domain residues 1793-1795 represent a factor IXa-interactive site in the tenase complex.
    Takeyama M; Furukawa S; Sasai K; Horiuchi K; Nogami K
    Biochim Biophys Acta Gen Subj; 2023 Aug; 1867(8):130381. PubMed ID: 37207906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
    Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
    Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII binding affects the mechanical unraveling of the A2 domain of von Willebrand factor.
    Cao W; Cao W; Zhang W; Zheng XL; Zhang XF
    J Thromb Haemost; 2020 Sep; 18(9):2169-2176. PubMed ID: 32544272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D' domain region Arg782-Cys799 of von Willebrand factor contributes to factor VIII binding.
    Przeradzka MA; van Galen J; Ebberink EHTM; Hoogendijk AJ; van der Zwaan C; Mertens K; van den Biggelaar M; Meijer AB
    Haematologica; 2020 Jun; 105(6):1695-1703. PubMed ID: 31558672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
    Favaloro EJ; Mohammed S; Vong R; Pasalic L
    Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
    J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
    Jacquemin M; Benhida A; Peerlinck K; Desqueper B; Vander Elst L; Lavend'homme R; d'Oiron R; Schwaab R; Bakkus M; Thielemans K; Gilles JG; Vermylen J; Saint-Remy JM
    Blood; 2000 Jan; 95(1):156-63. PubMed ID: 10607698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.